Polatuzumab vedotin plus rituximab, cyclophosphamide, doxorubicin, and prednisone (pola-r-chp) versus rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone (r-chop) therapy in patients with previously untreated diffuse large b-cell lymphoma (dlbcl): results from the phase iii polarix study

被引：0

作者：

Dietrich, Sascha ^{[1
]}

Tilly, Herve ^{[2
,3
]}

Morschhauser, Franck ^{[4
]}

Sehn, Laurie H. ^{[5
,6
]}

Friedberg, Jonathan W. ^{[7
]}

Trneny, Marek ^{[8
]}

Sharman, Jeff ^{[9
]}

Herbaux, Charles ^{[10
]}

Burke, John M. ^{[11
]}

Matasar, Matthew ^{[12
]}

Rai, Shinya ^{[13
]}

Izutsu, Koji ^{[14
]}

Mehta-Shah, Neha ^{[15
]}

Oberic, Lucie ^{[16
]}

Chauchet, Adrien ^{[17
]}

Jurczak, Wojciech ^{[18
]}

Song, Yu Qin ^{[19
]}

Greil, Richard ^{[20
,21
]}

Mykhalska, Larysa ^{[22
]}

Bergua Burgues, Juan Miguel ^{[23
]}

Cheung, Matthew C. ^{[24
]}

Pinto, Antonio ^{[25
]}

Shin, Ho-Jin ^{[26
]}

Hapgood, Greg ^{[27
]}

Munhoz, Eduardo ^{[28
]}

Salles, Gilles ^{[12
]}

机构：

[1] Univ Klinikum Heideberg, Klin Hamatol Onkol Rheumatol, Heidelberg, Germany

[2] Ctr Henri Becquerel, Rouen, France

[3] Univ Rouen, Rouen, France

[4] Univ Lille, Grp Rech Formes Injectables & Technol Associees, CHU Lille, Lille, France

[5] BC Canc Ctr Lymphoid Canc, Vancouver, BC, Canada

[6] Univ British Columbia, Vancouver, BC, Canada

[7] UR Med Wilmot Canc Ctr, Rochester, NY USA

[8] Charles Univ Prague, Gen Hosp, Fac Med 1, Prague, Czech Republic

[9] US Oncol, Willamette Valley Canc Inst, Eugene, OR USA

[10] CHU Montpellier, Montpellier, France

[11] US Oncol, Rocky Mt Canc Ctr, Aurora, CO USA

[12] Mem Sloan Kettering Canc Ctr, New York, NY USA

[13] Kindai Univ, Fac Med, Osaka Sayama City, Japan

[14] Natl Canc Ctr, Tokyo, Japan

[15] Washington Univ, St Louis, MO USA

[16] Toulouse Oncopole, Inst Univ Canc, Toulouse, France

[17] CHRU Besancon, Dept Hematol, Besancon, France

[18] Maria Sklodowska Curie Natl Res Inst Oncol, Krakow, Poland

[19] Peking Univ Canc Hosp, Beijing, Peoples R China

[20] Paracelsus Med Univ, Salzburg Canc Res Inst CCCIT, Salzburg, Austria

[21] Canc Cluster Salzburg, Salzburg, Austria

[22] Clin Hosp Feofaniya, Kiev, Ukraine

[23] Hosp San Pedro Alcantara, Caceres, Spain

[24] Univ Toronto, Odette Canc Ctr, Sunnybrook Hlth Sci Ctr, Toronto, ON, Canada

[25] IRCCS, Hematol Oncol Stem Cell Transplantat Unit, Ist Nazl Tumori, Fdn G Pascale, Naples, Italy

[26] Pusan Natl Univ, Sch Med, Med Res Inst, Pusan Natl Univ Hosp, Busan, South Korea

[27] Princess Alexandra Hosp, Brisbane, Qld, Australia

[28] Hosp Erasto Gaertner, Curitiba, Parana, Brazil

来源：

ONCOLOGY RESEARCH AND TREATMENT | 2022年 / 45卷 / SUPPL 3期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

891

引用

页码：165 / 165

页数：1

共 50 条

[31] ACCEPT: A phase Ib/II combination of acalabrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone (R-CHOP) for patients with diffuse large B-cell lymphoma (DLBCL)
Johnson, Peter W. M.
Caddy, Joshua
Cumin, Tom
Merton, Bridgen
Maishman, Tom
Galanopoulou, Angelic
Griffiths, Gareth
Davies, Andrew
CANCER RESEARCH, 2018, 78 (13)
[32] Expression of CD40 is a positive prognostic factor of diffuse large B-cell lymphoma treated with R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone)
Song, Guoqi
Ni, Huiyun
Zou, Linqing
Wang, Shukui
Tian, Fuliang
Liu, Hong
Cho, William C.
ONCOTARGETS AND THERAPY, 2016, 9 : 3799 - 3805
[33] Addition of venetoclax to rituximab cyclophosphamide, doxorubicin, vincristine, and prednisone in diffuse large cell B lymphoma
Calleja, Anne
HEMATOLOGIE, 2021, 27 (02): : 45 - 46
[34] Prognostic impact of sarcopenia in patients with diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone
Go, Se-Il
Park, Mi Jung
Song, Haa-Na
Kim, Hoon-Gu
Kang, Myoung Hee
Lee, Hyang Rae
Kim, Yire
Kim, Rock Bum
Lee, Soon Il
Lee, Gyeong-Won
JOURNAL OF CACHEXIA SARCOPENIA AND MUSCLE, 2016, 7 (05) : 567 - 576
[35] Glofitamab plus Pola-R-CHP in patients with previously untreated diffuse large B-cell lymphoma (DLBCL): Results from a phase Ib study
Dickinson, Michael
Viardot, Andreas
Marks, Reinhard
Topp, Max S.
Morschhauser, Franck
Jacobs, Benedikt
Tani, Monica
Bosch, Francesc
Esteban, Daniel
Cordoba, Raul
Kaufman, Derrick
Wu, Chun
Humphrey, Kathryn
Baumlin, Pauline
Barrett, Martin
Qayum, Naseer
Pinto, Antonio
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
[36] A phase III study of ibrutinib in combination with either bendamustine and rituximab (BR) or rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in patients with previously treated follicular lymphoma or marginal zone lymphoma.
Fowler, Nathan Hale
Hiddemann, Wolfgang
Leonard, John
Larsen, Julie S.
Rose, Esther
Zhuang, Sen Hong
Vermeulen, Jessica
Sun, Steven
Mentzer, Lisa
Yeh, Tzu-Min
Salles, Gilles A.
JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
[37] Cost-effectiveness of combination therapy of polatuzumab vedotin plus rituximab, cyclophosphamide, doxorubicin, and prednisolone for previously untreated diffuse large B-cell lymphoma in Japan
Mizuoka, Takashi
Sakamaki, Hiroyuki
Fuji, Shigeo
Saito, Shota
Murata, Tatsunori
Ohno, Shinya
Inubashiri, Naoki
Oshima, Tomoha
Yamamoto, Kazuhito
JOURNAL OF MEDICAL ECONOMICS, 2023, 26 (01) : 1122 - 1133
[38] Polatuzumab Vedotin Combined with Obinutuzumab, Cyclophosphamide, Doxorubicin, and Prednisone (G-CHP) for Patients with Previously Untreated Diffuse Large B-Cell Lymphoma (DLBCL): Preliminary Results of a Phase Ib/II Dose-Escalation Study
Forero-Torres, Andres
Kolibaba, Kathryn S.
Lamy, Thierry
Jones, Surai
Lee, Calvin
Sharman, Jeff
BLOOD, 2016, 128 (22)
[39] Efficacy and Safety of Polatuzumab Vedotin Plus Rituximab, Cyclophosphamide, Doxorubicin and Prednisone for Previously Untreated Diffuse Large B-Cell Lymphoma: A Real-World, Multi-Center, Retrospective Cohort Study
Zhao, Peiqi
Zhao, Shu
Huang, Chen
Li, Yajun
Wang, Jiesong
Xu, Junqing
Li, Lanfang
Qian, Zhengzi
Li, Wei
Zhou, Shiyong
Qiu, Lihua
Liu, Xianming
Chen, Ying
Jiang, Yanan
Zheng, Yanbin
Chen, Daoguang
Zhou, Hui
Gao, Yuhuan
Zhang, Qingyuan
Zhang, Huilai
HEMATOLOGICAL ONCOLOGY, 2025, 43 (01)
[40] Population Health and Economic Benefits of Pola-R-CHP versus R-CHOP in Patients With Previously Untreated Diffuse Large B-Cell Lymphoma (DLBCL) in the United States
Masaquel, Anthony
Li, Jia
Ho, Rodrigo
Fox, David
Rosettie, Katherine L.
El Moustaid, Fadoua
Qu, TingTing
Meng, Yang
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S438 - S439

← 1 2 3 4 5 →